321 related articles for article (PubMed ID: 23306411)
1. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
Stanos S
Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
[TBL] [Abstract][Full Text] [Related]
2. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.
Gudin J
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):136-43. PubMed ID: 22764852
[TBL] [Abstract][Full Text] [Related]
3. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
[TBL] [Abstract][Full Text] [Related]
4. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management.
Peppin JF; Coleman JJ; Kirsh KL
Issues Law Med; 2011; 27(2):91-119. PubMed ID: 22372206
[TBL] [Abstract][Full Text] [Related]
5. The Food and Drug Administration risk evaluation and mitigation strategy.
Craig DS
J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):145-8. PubMed ID: 20504137
[TBL] [Abstract][Full Text] [Related]
6. ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.
Cepeda MS; Coplan PM; Kopper NW; Maziere JY; Wedin GP; Wallace LE
Pain Med; 2017 Jan; 18(1):78-85. PubMed ID: 27373304
[TBL] [Abstract][Full Text] [Related]
7. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.
Bucher Bartelson B; Le Lait MC; Green JL; Cepeda MS; Coplan PM; Maziere JY; Wedin GP; Dart RC
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1061-1070. PubMed ID: 28758289
[TBL] [Abstract][Full Text] [Related]
8. Assessing the impact of the extended-release/long-acting opioid an-algesics risk evaluation and mitigation strategies on opioid prescrip-tion volume.
Divino V; Cepeda MS; Coplan P; Maziere JY; Yuan Y; Wade RL
J Opioid Manag; 2017; 13(3):157-168. PubMed ID: 28829517
[TBL] [Abstract][Full Text] [Related]
9. ER/LA opioid REMS and accredited education: Survey results provide insight into clinical roles, educational needs, and learner preferences.
Kear C; McKeithen T; Robertson S
Subst Abus; 2017; 38(2):145-149. PubMed ID: 28418777
[TBL] [Abstract][Full Text] [Related]
10. Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms.
Food And Drug Administration, Public Health Service, U.S. Department Of Health And Human Services
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):123-6. PubMed ID: 22764848
[TBL] [Abstract][Full Text] [Related]
11. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).
Sloan PA
J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921
[No Abstract] [Full Text] [Related]
12. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.
Slevin KA; Ashburn MA
J Opioid Manag; 2011; 7(2):109-15. PubMed ID: 21561034
[TBL] [Abstract][Full Text] [Related]
13. Postmarketing studies program to assess the risks and benefits of long-term use of extended-release/long-acting opioids among chronic pain patients.
Coplan PM; Cepeda MS; Petronis KR; DeVeaugh-Geiss A; Barsdorf AI; Kern DM; Fanelli R
Postgrad Med; 2020 Jan; 132(1):44-51. PubMed ID: 31721609
[No Abstract] [Full Text] [Related]
14. Blueprint for prescriber continuing education program.
Center For Drug Evaluation And Research Food And Drug Administration
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):127-30. PubMed ID: 22764849
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review.
Heyward J; Olson L; Sharfstein JM; Stuart EA; Lurie P; Alexander GC
JAMA Intern Med; 2020 Feb; 180(2):301-309. PubMed ID: 31886822
[TBL] [Abstract][Full Text] [Related]
16. US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioids: pros and cons, and a European perspective.
Mercadante S; Craig D; Giarratano A
Drugs; 2012 Dec; 72(18):2327-32. PubMed ID: 23116252
[TBL] [Abstract][Full Text] [Related]
17. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
[TBL] [Abstract][Full Text] [Related]
18. Increase your Confidence in Opioid Prescribing: Marketing Messages in Continuing Medical Education Activities on ER/LA Opioids.
Goodwin B; Lim HD; Butler J; Paglia D; Dempsey MT; O Connor B; Fugh-Berman A
Pain Physician; 2021 Aug; 24(5):E529-E538. PubMed ID: 34323440
[TBL] [Abstract][Full Text] [Related]
19. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS).
Nelson LS; Perrone J
JAMA; 2012 Aug; 308(5):457-8. PubMed ID: 22851109
[No Abstract] [Full Text] [Related]
20. Clinical strategies for the primary health care professional to minimize prescription opioid abuse.
Gudin JA
Postgrad Med; 2012 May; 124(3):131-8. PubMed ID: 22691907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
